Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Insmed Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Insmed Inc has 18 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either Insmed Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In October 2016, we entered into the AZ License Agreement, pursuant to which AstraZeneca granted us exclusive global rights for the purpose of developing and commercializing AZD7986 (which we renamed brensocatib).”
FILING10-K0001104506-26-000009cik 0001104506
“In September 2018, we entered into an agreement (the Lease) with Bridgewater Biotech Center LLC (assumed from Exeter 700 Route 202/206, LLC) to lease 117,022 square feet of office space located in Bridgewater, New Jersey for our corporate headquarters.”
FILING10-K0001104506-26-000009cik 0001104506
“In addition, Esteve manufactures the active pharmaceutical ingredient for brensocatib, and Patheon Inc. manufactures our current supply of BRINSUPRI.”
FILING10-K0001104506-26-000009cik 0001104506
“In October 2022, we entered into the Royalty Financing Agreement with OrbiMed, whereby OrbiMed paid us $150.0 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4.0% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, which includes BRINSUPRI.”
FILING10-K0001104506-26-000009cik 0001104506
“In July 2014, we entered into a Commercialization Agreement with PARI for the manufacture and supply of Lamira, which is an e-Flow ® nebulizer modified and optimized for use with ARIKAYCE.”
FILING10-K0001104506-26-000009cik 0001104506
“In addition, Esteve manufactures the active pharmaceutical ingredient for brensocatib, and Patheon Inc. manufactures our current supply of BRINSUPRI.”
FILING10-K0001104506-26-000009cik 0001104506
“In January 2024, we entered into certain agreements with Patheon Inc., a wholly-owned subsidiary of Thermo Fisher, related to the manufacture and supply of commercial brensocatib products, including BRINSUPRI, for our commercial needs and brensocatib for our clinical needs by Patheon Inc.”
FILING10-K0001104506-26-000009cik 0001104506
“In October 2022, we entered into a $350.0 million Tranche A Term Loan with Pharmakon that would have matured on October 19, 2027.”
FILING10-K0001104506-26-000009cik 0001104506
“In April 2020, we entered into a master services agreement with PPD Development, L.P. (PPD) pursuant to which we retained PPD to perform clinical development services in connection with certain of our clinical research programs.”
FILING10-K0001104506-26-000009cik 0001104506
“In connection with our purchase of INS1148, we became exclusive licensee to certain patents from the Regents of the University of Michigan (Michigan), including US Patent Nos. 9,353,178, 9,790,272 and 10,501,535.”
FILING10-K0001104506-26-000009cik 0001104506
“In December 2023, we entered into a license agreement with NCH, pursuant to which we were granted an exclusive license under certain patents covering INS1202, to develop and commercialize INS1202 on a worldwide basis.”
FILING10-K0001104506-26-000009cik 0001104506
“Resilience manufactures placebo for our clinical trials and our current supply of ARIKAYCE for commercial sale.”
FILING10-K0001104506-26-000009cik 0001104506
“In the first quarter of 2021, we entered into a sales agreement with SVB Leerink LLC (now known as Leerink Partners LLC) (Leerink Partners), to sell shares of our common stock, with aggregate gross sales proceeds of up to $250.0 million, from time to time, through an "at the market" equity offering program (the ATM program), under which Leerink Partners acted as sales agent.”
FILING10-K0001104506-26-000009cik 0001104506
“In October 2024, we entered into the A&R Loan Agreement, as amended July 10, 2025, with BioPharma Credit PLC, BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon, and the guarantors party to such agreement.”
FILING10-K0001104506-26-000009cik 0001104506
“In October 2024, we entered into the A&R Loan Agreement, as amended July 10, 2025, with BioPharma Credit PLC, BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon, and the guarantors party to such agreement.”
FILING10-K0001104506-26-000009cik 0001104506
“In October 2024, we entered into the A&R Loan Agreement, as amended July 10, 2025, with BioPharma Credit PLC, BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon, and the guarantors party to such agreement.”
FILING10-K0001104506-26-000009cik 0001104506
“In December 2025, we acquired the global rights to O pSCF (renamed INS1148) from Opsidio.”
FILING10-K0001104506-26-000009cik 0001104506
“In January 2023, we acquired Vertuis, a privately held, pre-clinical stage company.”
FILING10-K0001104506-26-000009cik 0001104506
“A significant portion of our current ARIKAYCE and BRINSUPRI revenues in the US are dependent on Medicare reimbursement, and we expect that trend to continue.”
FILING10-K0001104506-26-000009cik 0001104506
“We are required to deliver to Patheon Inc. the active pharmaceutical ingredient needed to manufacture BRINSUPRI.”
FILING10-K0001104506-26-000009cik 0001104506
Watchlist prices, news filtered to it, and its next report on your desk.
INSM (Insmed Inc) has 18 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.